-
Mashup Score: 0Immunotherapy May Be Underused in Endometrial Cancer - 6 hour(s) ago
Suboptimal rates of dMMR testing and immunotherapy use suggest “a need for ongoing clinician and patient education, given the survival benefit of immunotherapy in recurrent endometrial cancer,” researchers concluded.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5
Study results “provide strong support for integrating symptom screening and care pathways into routine clinical care,” according to researchers
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Hem/OncsTweet-
“Symptom screening w/symptom feedback & symptom management care pathways improved SSPedi scores and ⬆️ symptom-specific interventions among pediatric patients w/cancer” Screening Reduces Symptom Burden in Pediatric Cancer Patients @oncologynursing https://t.co/0sfQbJ4YoT
-
-
Mashup Score: 0FDA Approves Obecabtagene Autoleucel for Adults With BCP-ALL - 4 day(s) ago
The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
The @US_FDA has approved obecabtagene autoleucel (Aucatzyl), a CD19-directed CAR T-cell therapy, to treat adults with R/R B-cell precursor acute #lymphoblasticLeukemia. https://t.co/uFUncsoTNL #leusm
-
-
Mashup Score: 0
Phase 2 trial results support further development of camizestrant for the treatment of estrogen receptor-positive, HER2-negative breast cancer, according to researchers.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Camizestrant significantly improved PFS compared to fulvestrant in patients with ER-positive, HER2-negative #breastcancer. Published in @TheLancetOncol. https://t.co/ytg6w5kT11 #bcsm
-
-
Mashup Score: 0
“Interventions to improve health literacy should be further investigated or developed to assist individuals with limited health literacy in navigating the health care system, particularly as it relates to the complex nature of cancer care,” researchers concluded.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Limited #healthLiteracy is associated with a higher risk of #frailty and inferior health-related quality of life among older adults with cancer. Published in @JCOOP_ASCO. https://t.co/Zjoevm7ZEN #HRQOL
-
-
Mashup Score: 0Toripalimab Plus Chemo: A First-Line Option for ES-SCLC? - 6 day(s) ago
Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed to confirm that.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Phase 3 trial results support toripalimab plus etoposide and platinum-based chemotherapy as a first-line treatment option for patients with extensive-stage small cell #lungcancer, according to researchers. Reported in @JAMAOnc. https://t.co/wYHN4oZdEz #SCLC #lcsm
-
-
Mashup Score: 0
Pegylated liposomal doxorubicin showed promise in a single-arm trial, but randomized trials are needed, according to researchers.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Pegylated liposomal doxorubicin has demonstrated safety and efficacy in patients with partially platinum-sensitive, platinum-resistant, or platinum-refractory #ovarianCancer. Published in @OncJournal. https://t.co/dovYpB9kFh #gyncsm
-
-
Mashup Score: 0
“he professional licensure system … may be institutionally ill-suited to combat the diffuse, intractable, and largely public health-related harms arising from physician-spread misinformation,” according to Richard S. Saver, JD.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
A large study suggests that, across the most populous US states, few physicians are disciplined for spreading #medicalMisinformation. Published in @JAMANetworkOpen. https://t.co/97qNXTsEt7
-
-
Mashup Score: 0
Clinicians should have a standard approach for discussing the risk of adverse events associated with immune checkpoint inhibitors, researchers say.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
As many as 40% of #cancer patients receiving immune checkpoint inhibitors experience immune-related adverse events. https://t.co/utExqDb5Ec
-
-
Mashup Score: 4
Researchers provided recommendations for managing adverse events in patients with renal cell carcinoma receiving cabozantinib and nivolumab.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Researchers have provided recommendations for managing AEs in patients with RCC receiving cabozantinib and nivolumab. Presented at #IKCSNA24. @KidneyCancer #gucsm https://t.co/sX1Fjz9sO3
-
Immunotherapy and testing for mismatch repair deficiency may be underused in patients with #endometrialcancer in the United States, researchers say. Reported in @AJOG_thegray. https://t.co/Aot7gFgwN7 #gyncsm